Vogenx, Inc. Cash and Restricted Cash
Vogenx, Inc. (VOGX) had Cash and Restricted Cash of $193.02 thousand as of 2026-06-30, per its 10-Q filed 2026-09-17.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-17
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $193.02K.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $601.01K.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $390.28K.
- 2024-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $962.92K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $193.02K 10-Q · filed 2026-09-17 |
| 2025-12-31 | $601.01K 10-Q · filed 2026-09-17 |
| 2025-06-30 | $390.28K 10-Q · filed 2026-09-17 |
| 2024-12-31 | $962.92K 10-Q · filed 2026-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |